CSCI COSCIENS Biopharma
- 5.650
- -0.360-5.99%
- 5.650
- 0.0000.00%
COSCIENS Biopharma News
6-K: Report of foreign private issuer (related to financial reporting)
6-K: Report of foreign private issuer (related to financial reporting)
AEterna Zentaris | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
AEterna Zentaris | 20-F/A: Registration statement / Annual report / Transition report (Amendment)
AEterna Zentaris | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
AEterna Zentaris | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
AEterna Zentaris | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
AEterna Zentaris | 424B3: Prospectus
AEterna Zentaris | 424B3: Prospectus
AEterna Zentaris | 424B3: Prospectus
AEterna Zentaris | 424B3: Prospectus
AEterna Zentaris | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
AEterna Zentaris | SC 13G: Statement of acquisition of beneficial ownership by individuals-Goodwood Fund(7.2%),Goodwood, Inc.(7.2%), etc.
AEterna Zentaris | EFFECT: Others
AEterna Zentaris | EFFECT: Others
AEterna Zentaris | EFFECT: Others
AEterna Zentaris | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing
AEterna Zentaris | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing
AEterna Zentaris | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
AEterna Zentaris | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing
Analysis
Price Target
No Data
